BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33893086)

  • 21. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
    Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
    Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
    Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
    Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma.
    Vaillant C; Valdivieso P; Nuciforo S; Kool M; Schwarzentruber-Schauerte A; Méreau H; Cabuy E; Lobrinus JA; Pfister S; Zuniga A; Frank S; Zeller R
    PLoS One; 2015; 10(4):e0124870. PubMed ID: 25901736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a SUFU germline mutation in a family with Gorlin syndrome.
    Pastorino L; Ghiorzo P; Nasti S; Battistuzzi L; Cusano R; Marzocchi C; Garrè ML; Clementi M; Scarrà GB
    Am J Med Genet A; 2009 Jul; 149A(7):1539-43. PubMed ID: 19533801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same.
    Huq AJ; Walsh M; Rajagopalan B; Finlay M; Trainer AH; Bonnet F; Sevenet N; Winship IM
    Fam Cancer; 2018 Oct; 17(4):601-606. PubMed ID: 29356994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG).
    Guerrini-Rousseau L; Smith MJ; Kratz CP; Doergeloh B; Hirsch S; Hopman SMJ; Jorgensen M; Kuhlen M; Michaeli O; Milde T; Ridola V; Russo A; Salvador H; Waespe N; Claret B; Brugieres L; Evans DG
    Fam Cancer; 2021 Oct; 20(4):317-325. PubMed ID: 33860896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
    Niesen J; Ohli J; Sedlacik J; Dührsen L; Hellwig M; Spohn M; Holsten T; Schüller U
    Cancer Lett; 2020 May; 477():10-18. PubMed ID: 32112900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of suppressor-of-fused function promotes tumorigenesis.
    Lee Y; Kawagoe R; Sasai K; Li Y; Russell HR; Curran T; McKinnon PJ
    Oncogene; 2007 Sep; 26(44):6442-7. PubMed ID: 17452975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hedgehog pathway permissive conditions allow generation of immortal cell lines from granule cells derived from cancerous and non-cancerous cerebellum.
    Heil C
    Open Biol; 2019 Jan; 9(1):180145. PubMed ID: 30958113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing Sufu gene dosage reveals its unorthodox role in promoting polydactyly and medulloblastoma tumorigenesis.
    Han B; Wang Y; Yue S; Zhang YH; Kuang L; Gao BB; Wang Y; Zhang Z; Pu X; Wang XF; Hui CC; Yu TT; Liu C; Cheng SY
    JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38358805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of sonic hedgehog-GLI1 downstream target genes PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKX2.2 and their epigenetic status in medulloblastoma and astrocytoma.
    Shahi MH; Afzal M; Sinha S; Eberhart CG; Rey JA; Fan X; Castresana JS
    BMC Cancer; 2010 Nov; 10():614. PubMed ID: 21059263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort.
    Kloth K; Obrecht D; Sturm D; Pietsch T; Warmuth-Metz M; Bison B; Mynarek M; Rutkowski S
    Front Oncol; 2021; 11():756025. PubMed ID: 34888241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas.
    Grausam KB; Dooyema SDR; Bihannic L; Premathilake H; Morrissy AS; Forget A; Schaefer AM; Gundelach JH; Macura S; Maher DM; Wang X; Heglin AH; Ge X; Zeng E; Puget S; Chandrasekar I; Surendran K; Bram RJ; Schüller U; Talyor MD; Ayrault O; Zhao H
    Cancer Res; 2017 Jul; 77(14):3766-3777. PubMed ID: 28490517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel PTCH1 Frameshift Mutation Leading to Nevoid Basal Cell Carcinoma Syndrome.
    Durmaz CD; Evans G; Smith MJ; Ertop P; Akay BN; Tuncalı T
    Cytogenet Genome Res; 2018; 154(2):57-61. PubMed ID: 29544218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and mutational profiles of adult medulloblastoma groups.
    Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a neuronal transcription factor network involved in medulloblastoma development.
    Lastowska M; Al-Afghani H; Al-Balool HH; Sheth H; Mercer E; Coxhead JM; Redfern CP; Peters H; Burt AD; Santibanez-Koref M; Bacon CM; Chesler L; Rust AG; Adams DJ; Williamson D; Clifford SC; Jackson MS
    Acta Neuropathol Commun; 2013 Jul; 1():35. PubMed ID: 24252690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation.
    Kijima C; Miyashita T; Suzuki M; Oka H; Fujii K
    Fam Cancer; 2012 Dec; 11(4):565-70. PubMed ID: 22829011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age.
    Brugières L; Remenieras A; Pierron G; Varlet P; Forget S; Byrde V; Bombled J; Puget S; Caron O; Dufour C; Delattre O; Bressac-de Paillerets B; Grill J
    J Clin Oncol; 2012 Jun; 30(17):2087-93. PubMed ID: 22508808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
    Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
    Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.